Hematology Unit, Department of Clinical Pathology, Mansoura University, Egypt.
Oncology Unit, Mansoura University Oncology Center, Mansoura University, Egypt.
Asian Pac J Cancer Prev. 2023 Jun 1;24(6):1943-1948. doi: 10.31557/APJCP.2023.24.6.1943.
little is known regarding the prognostic value of soluble CD200 (sCD200)in chronic lymphocytic leukemia patients. Therefore, the objective of our study is to address the prognostic value of sCD200 antigen concentration on CLL patients outcome.
Determination of serum sCD200 was done using ELISA kit in 158 CLL patients at diagnosis before start of therapy beside 21 healthy controls.
sCD200 concentration levels was significantly higher in CLL patients as compared to healthy controls. High sCD200 was associated with poor prognostic markers (high expression of CD38+% and ZAP70+, high LDH, high risk Rai stages, unfavorable cytogenetic finding, time to first treatment (TTT) as well as patients outcome (P<0.001 for All). sCD200 at cut-off value ( 752.5 pg/ml) could predicts TTT with specificity 83.4%.
Determination of sCD200 concentration levels at diagnosis could be used as a prognostic biomarker in CLL patients.
关于可溶性 CD200（sCD200）在慢性淋巴细胞白血病（CLL）患者中的预后价值知之甚少。因此，我们研究的目的是探讨 sCD200 抗原浓度对 CLL 患者预后的预测价值。
在开始治疗前，通过 ELISA 试剂盒测定 158 例 CLL 患者和 21 例健康对照者的血清 sCD200。
与健康对照组相比，CLL 患者的 sCD200 浓度明显升高。高 sCD200 与不良预后标志物（高表达 CD38+%和 ZAP70+、高 LDH、高风险 Rai 分期、不良细胞遗传学发现、首次治疗时间（TTT）以及患者预后相关（所有 P<0.001）。sCD200 在截断值（752.5 pg/ml）时可预测 TTT，特异性为 83.4%。
在诊断时测定 sCD200 浓度水平可作为 CLL 患者的预后生物标志物。
